CAMBRIDGE, Mass., April 2, 2026
Vedanta Biosciences announced that its pivotal Phase 3 RESTORATiVE303 clinical trial of VE303 will continue as planned following a positive interim analysis by an independent Data Monitoring Committee (DMC), marking a significant milestone in the development of microbiome-based therapies for recurrent Clostridioides difficile infection (CDI). The committee’s recommendation, based on an unblinded review of safety and efficacy data, confirmed that the study has exceeded predefined futility thresholds with no new safety concerns, reinforcing confidence in VE303 as a potential first-in-class live biotherapeutic product (LBP) targeting a major unmet medical need.
Positive Interim Analysis Validates Clinical Potential
The interim analysis was conducted after 50% of enrolled patients reached the Week 8 primary efficacy endpoint, a critical milestone in the study design. According to the findings, VE303 demonstrated sufficient efficacy to surpass futility criteria, while maintaining a strong safety profile with no significant adverse events observed.
This outcome supports the continuation of the trial without modifications and highlights the robust clinical design of the RESTORATiVE303 study, which is a randomized, double-blind, placebo-controlled, multinational Phase 3 trial. The trial aims to evaluate the efficacy of VE303 in preventing recurrence of CDI, a condition associated with high morbidity and recurrence rates.
Innovative Microbiome Therapy Targets Unmet Need
Advertisement
VE303 represents a novel, orally administered live biotherapeutic composed of a defined consortium of eight bacterial strains, designed to restore gut microbiome balance and prevent CDI recurrence. Unlike traditional fecal microbiota-based approaches, VE303 is developed from pure clonal bacterial cell banks, ensuring consistency, scalability, and regulatory compliance.
In earlier Phase 2 studies, VE303 demonstrated a 30.5% absolute risk reduction in CDI recurrence, translating to a greater than 80% reduction in recurrence odds compared to placebo, underscoring its transformative therapeutic potential. Additionally, the therapy has received FDA Orphan Drug Designation and Fast Track Designation, further supporting its accelerated clinical development pathway.
Global Trial Expansion and Regulatory Pathway
The RESTORATiVE303 trial is currently being conducted across more than 150 clinical sites in approximately 20 countries, reflecting its global scale and significance. Vedanta Biosciences expects to complete enrollment in the second half of 2026, with a second interim analysis planned within the same timeframe, paving the way toward potential Biologics License Application (BLA) submission to the FDA. The trial focuses on patients with one or more recurrent CDI episodes, a population at high risk for further recurrence and complications. The study’s primary endpoint—CDI recurrence rate at Week 8—serves as a key regulatory benchmark, supporting future approval decisions.
Addressing a High-Burden Infectious Disease
Clostridioides difficile infection remains a significant global healthcare challenge, affecting approximately 175,000 patients annually in the United States alone and contributing to around 20,000 deaths each year. Recurrence is common, with each episode increasing the likelihood of future infections, leading to prolonged hospitalization, increased healthcare costs, and reduced quality of life. VE303’s targeted microbiome-based mechanism offers a promising solution by addressing the underlying dysbiosis driving recurrence, rather than solely treating symptoms. This approach represents a paradigm shift in infectious disease management, aligning with modern strategies focused on precision microbiome therapeutics and long-term disease prevention.
Source: Vedanta Biosciences press release
